#AusperBio
LightNews LightNews
sprintome.bsky.social
Superluminal raises $60M and AusperBio secures $120M in latest Fierce Biotech Fundraising Tracker. Biotechs continue to attract substantial venture capital rounds of $50M or more.
September 5, 2026 at 10:01 PM
sprintome.bsky.social
Biotech companies Superluminal and AusperBio raise $60M and $120M respectively in recent funding rounds tracked by Fierce Biotech. These substantial investments signal strong investor confidence in the biotech sector.
September 4, 2026 at 8:01 PM
portfolio-alert.bsky.social
RA Capital: AusperBio
SOSV: TopologiQ
StageOne Ventures: Gain Security
Stripes: Baseten
September 1, 2026 at 10:39 AM
startup-alert.bsky.social
RA Capital: AusperBio
Seven Seven Six: TMRW FlagCo.
SOSV: TopologiQ
Stripes: Baseten
Ten Eleven: Caspia
True Ventures: Develocity
September 1, 2026 at 6:40 AM
firstwordgroup.com
AusperBio closes $120M series C to propel hep B therapeutics firstwordpharma.com/story/7922727
August 28, 2026 at 3:29 PM
openbionews.com
BioNTech and Genentech stop a personalized cancer vaccine trial, AusperBio banks $120M for hepatitis B, BioXcel files bankruptcy with a Teva asset sale — plus Genentech's $1B ADC deal with DualityBio and FDA moves on LISRAYA.
https://openbionews.com/analysis/daily-bio-news-summary-2026-08-28/
Daily Bio News Summary — 2026-08-28: BioNTech Vaccine Setback, AusperBio
Sixteen articles from 7 sources covering BioNTech and Genentech
openbionews.com
August 29, 2026 at 2:06 AM
newsen.bsky.social
AusperBio Secures $120 Million in Series C Financing to Propel AHB-137 and HBV Therapies to Market#United_States#San_Francisco#AusperBio#AHB-137#HBV_Therapies
AusperBio Secures $120 Million in Series C Financing to Propel AHB-137 and HBV Therapies to Market
AusperBio Therapeutics has successfully completed a $120 million Series C financing to enhance the development of AHB-137, targeting chronic hepatitis B therapies. This funding will enable crucial advancements.
third-news.com
August 28, 2026 at 12:09 AM
l2plabs.bsky.social
AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies
Financing supports advancement of AHB-137 toward potential commercialization, including its Phase 3 registrational program and commercialization readiness Proceeds will also accelerate AHB-171 and next-generation combination approaches designed to advance functional cure for chronic...
dlvr.it
August 28, 2026 at 12:04 AM
ninapryce.bsky.social
AusperBio's AHB-137 hit a 30% functional cure rate in a chronic hepatitis B patient subset - a disease long considered incurable.

https://yespress.io/ausperbio?utm_source=bluesky&utm_medium=social via Yespress
AusperBio - Chasing a Functional Cure for Hepatitis B | Profile
A San Mateo biotech developing antisense oligonucleotide therapies for a functional cure for chronic hepatitis B. Lead candidate AHB-137 is advancing toward Phase III.
yespress.io
August 19, 2026 at 11:45 AM
newsen.bsky.social
AusperBio Begins Clinical Trials for Groundbreaking HBV Treatment AHB-171#USA#San_Francisco#AusperBio#Hepatitis_B#AHB-171
AusperBio Begins Clinical Trials for Groundbreaking HBV Treatment AHB-171
AusperBio initiates patient dosing in a clinical trial for AHB-171, targeting chronic hepatitis B with advanced oligonucleotide therapy.
third-news.com
August 3, 2026 at 9:41 AM
l2plabs.bsky.social
AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171
SAN FRANCISCO, Aug. 3, 2026 /PRNewswire/ -- AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a near-commercial Biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other...
dlvr.it
August 3, 2026 at 9:32 AM
tamilthinkdaily.bsky.social
AusperBio தொடர் B2 நிதியுதவியில் $63 மில்லியன் திரட்டுகிறது

AusperBio தெரபியூட்டிக்ஸ், Inc. மற்றும் Ausper Biopharma Co., Ltd. (கூட்டாக AusperBio), நாள்பட்ட ஹெபடைடிஸ் பி (CHB)க்கான செயல்பாட்டு சிகிச்சையை அடைய இலக்கு வைக்கப்பட்ட ஒலிகோநியூக்ளியோடைடு சிகிச்சைகளை மேம்படுத்துவதற்காக அர்ப்பணிக்கப்பட்ட…
AusperBio தொடர் B2 நிதியுதவியில் $63 மில்லியன் திரட்டுகிறது
AusperBio தெரபியூட்டிக்ஸ், Inc. மற்றும் Ausper Biopharma Co., Ltd. (கூட்டாக AusperBio), நாள்பட்ட ஹெபடைடிஸ் பி (CHB)க்கான செயல்பாட்டு சிகிச்சையை அடைய இலக்கு வைக்கப்பட்ட ஒலிகோநியூக்ளியோடைடு சிகிச்சைகளை மேம்படுத்துவதற்காக அர்ப்பணிக்கப்பட்ட ஒரு தனியார் மருத்துவ-நிலை உயிரி தொழில்நுட்ப நிறுவனமான S. CHB க்கு ஒரு செயல்பாட்டு சிகிச்சையை அடைவதற்கான AusperBio இன் திருப்புமுனை அணுகுமுறையின் மீதான நம்பிக்கையை அடிக்கோடிட்டுக் காட்டும் வகையில், நிறுவனத்தின் தற்போதைய முதலீட்டாளர்களின் சிண்டிகேட் மூலம் நிதியுதவி வலுவாக ஆதரிக்கப்பட்டது. ஹான்காங் கேபிடல், சிடிஹெச் இன்வெஸ்ட்மென்ட்ஸ், யுவான்பியோ வென்ச்சர் கேபிடல், ஷெர்பா கேபிடல் மற்றும் ஜெனிசிஸ் கேபிட்டல் ஆகியவற்றின் தொடர்ச்சியான பங்கேற்புடன், கிமிங் வென்ச்சர் பார்ட்னர்ஸ் மற்றும் உலக அளவில் புகழ்பெற்ற மூலோபாய முதலீட்டாளர் இந்தச் சுற்றுக்கு தலைமை தாங்கினார்.
tamil.thinkdaily.in
December 14, 2025 at 10:37 PM
longtail-news.bsky.social
Feed: "Clinical Trials Arena"
By: sdebbarma on Monday, September 22, 2025
AusperBio completes enrolment in Phase II chronic hepatitis B trials
AusperBio Therapeutics and Ausper Biopharma (jointly known as AusperBio) have completed participant enrolment in two Phase II studies evaluating AHB-137.
www.clinicaltrialsarena.com
September 22, 2025 at 4:46 PM
projesh.bsky.social
🇨🇳 has no time to celebrate the new year

AusperBio, Calo, Captain Fresh, and more raised funds this week.
🇨🇳 has no time to celebrate the new year
AusperBio, Calo, Captain Fresh, and more raised funds this week.
thelegendofhanuman.in
January 4, 2025 at 8:47 PM
newsen.bsky.social
AusperBio Achieves Significant Milestone with Patient Enrollment in AUSHINE Study for Chronic Hepatitis B#USA#San_Francisco#AusperBio#AHB-137#Chronic_Hepatitis_B
AusperBio Achieves Significant Milestone with Patient Enrollment in AUSHINE Study for Chronic Hepatitis B
AusperBio has successfully completed patient enrollment in its Phase III AUSHINE study, crucial for addressing chronic hepatitis B with AHB-137.
third-news.com
December 22, 2025 at 10:18 AM
newsen.bsky.social
AusperBio's AHB-137 Shows Promising Results for Hepatitis B Treatment#USA#San_Francisco#AusperBio#Hepatitis_B#AHA-137
AusperBio's AHB-137 Shows Promising Results for Hepatitis B Treatment
AusperBio's recent findings on AHB-137's effectiveness in treating chronic hepatitis B offer new hope, achieving a 30% functional cure rate in patients.
third-news.com
December 12, 2025 at 2:26 PM
newsen.bsky.social
AusperBio Showcases 48-Week Phase II Data of AHB-137 for Chronic Hepatitis B at AASLD 2025#Washington_D.C.#AusperBio#AHB-137#Hepatitis_B
AusperBio Showcases 48-Week Phase II Data of AHB-137 for Chronic Hepatitis B at AASLD 2025
At the AASLD 2025 Annual Meeting, AusperBio revealed promising 48-week Phase II data for AHB-137, enhancing treatment for chronic hepatitis B.
third-news.com
November 8, 2025 at 1:34 PM
newsen.bsky.social
AusperBio Secures $63 Million to Transform Hepatitis B Treatments with Innovative Therapies#USA#San_Francisco#AusperBio#AHB-137#Med-Oligo
AusperBio Secures $63 Million to Transform Hepatitis B Treatments with Innovative Therapies
AusperBio Therapeutics has successfully closed $63 million in Series B2 financing to advance innovative therapies aimed at curing chronic hepatitis B.
third-news.com
September 22, 2025 at 12:36 AM
newsen.bsky.social
AusperBio Achieves Milestone in AHB-137 Phase II Trials for Chronic Hepatitis B#USA#San_Francisco#AusperBio#AHB-137#Hepatitis_B
AusperBio Achieves Milestone in AHB-137 Phase II Trials for Chronic Hepatitis B
AusperBio Therapeutics has completed the enrollment for two pivotal Phase II trials of AHB-137, a potential treatment for chronic hepatitis B. The trials could redefine treatment strategies in the field.
third-news.com
September 19, 2025 at 12:48 AM
newsen.bsky.social
AusperBio Advances AHB-137 into Phase III Clinical Trials to Combat Chronic Hepatitis B in China#China#San_Francisco#AusperBio#AHB-137#Chronic_Hepatitis_B
AusperBio Advances AHB-137 into Phase III Clinical Trials to Combat Chronic Hepatitis B in China
AusperBio has received approval to initiate Phase III trials for AHB-137, a promising treatment for chronic hepatitis B, from China's drug evaluation body.
third-news.com
July 21, 2025 at 7:52 PM
newsen.bsky.social
AusperBio Secures $50 Million Funding to Enhance Chronic Hepatitis B Treatments#USA#San_Francisco#AusperBio#AHB-137#Hepatitis_B
AusperBio Secures $50 Million Funding to Enhance Chronic Hepatitis B Treatments
AusperBio Therapeutics has successfully completed a $50 million Series B+ financing round to further develop innovative treatments for chronic hepatitis B.
third-news.com
May 28, 2025 at 4:29 PM
newsen.bsky.social
AusperBio Showcases Promising Clinical Data for AHB-137 During EASL Congress 2025#United_States#San_Francisco#AusperBio#AHB-137#EASL_Congress
AusperBio Showcases Promising Clinical Data for AHB-137 During EASL Congress 2025
AusperBio Therapeutics presents significant interim data for AHB-137 at the EASL Congress 2025, spotlighting its potential in hepatitis B treatment.
third-news.com
May 7, 2025 at 7:08 PM
newsen.bsky.social
AusperBio Achieves $73 Million in Series B Funding to Combat Chronic Hepatitis B#USA#San_Francisco#AusperBio#AHB-137#Hepatitis_B
AusperBio Achieves $73 Million in Series B Funding to Combat Chronic Hepatitis B
AusperBio has successfully closed a $73 million Series B financing round to enhance its efforts in developing a functional cure for chronic hepatitis B, showcasing investor confidence.
third-news.com
December 26, 2024 at 11:14 PM
startupwire.bsky.social
AusperBio Therapeutics, a clinical-stage biotechnology company, has successfully raised $73 million in a Series B financing round #biotech
startupwire.in/biotech/ausp...
AusperBio Therapeutics Completes $73 Million Series B
AusperBio a clinical-stage biotechnology company specializing in targeted oligonucleotide therapies, has successfully completed a $73 million
startupwire.in
December 27, 2024 at 11:28 AM